ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 566,42
-0,56%
Dow Jones
39 127,80
0,00%
DAX
18 205,63
0,23%
Brent Oil
85,035
0,67%
Bitcoin
61 151,81
0,56%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. iTeos Therapeutics Inc (ITOS)

  7. iTeos Therapeutics Inc (ITOS) Actualités

ITOS

iTeos Therapeutics (ITOS)

iTeos Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ITOS
DateHeureSourceTitreSymboleSociété
17/06/202415h00GlobeNewswire Inc.iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung CancerNASDAQ:ITOSiTeos Therapeutics Inc
14/06/202402h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITOSiTeos Therapeutics Inc
13/06/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITOSiTeos Therapeutics Inc
10/05/202422h35Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ITOSiTeos Therapeutics Inc
10/05/202414h31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ITOSiTeos Therapeutics Inc
10/05/202414h26GlobeNewswire Inc.iTeos Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:ITOSiTeos Therapeutics Inc
10/05/202414h24GlobeNewswire Inc.iTeos Therapeutics Announces $120 Million Registered Direct OfferingNASDAQ:ITOSiTeos Therapeutics Inc
07/04/202422h30GlobeNewswire Inc.iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024NASDAQ:ITOSiTeos Therapeutics Inc
08/03/202402h00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ITOSiTeos Therapeutics Inc
06/03/202413h19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ITOSiTeos Therapeutics Inc
06/03/202413h09Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ITOSiTeos Therapeutics Inc
06/03/202413h01GlobeNewswire Inc.iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of DirectorsNASDAQ:ITOSiTeos Therapeutics Inc
06/03/202413h00GlobeNewswire Inc.iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:ITOSiTeos Therapeutics Inc
05/03/202422h30GlobeNewswire Inc.iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024NASDAQ:ITOSiTeos Therapeutics Inc
01/03/202413h00GlobeNewswire Inc.iTeos to Participate in Upcoming Investor ConferencesNASDAQ:ITOSiTeos Therapeutics Inc
08/01/202413h00GlobeNewswire Inc.iTeos Announces 2024 Strategic Priorities and Anticipated MilestonesNASDAQ:ITOSiTeos Therapeutics Inc
03/01/202413h00GlobeNewswire Inc.iTeos to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ITOSiTeos Therapeutics Inc
21/11/202313h00GlobeNewswire Inc.iTeos to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:ITOSiTeos Therapeutics Inc
07/11/202313h00GlobeNewswire Inc.iTeos Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:ITOSiTeos Therapeutics Inc
11/10/202323h55PR Newswire (US)NCR Atleos Set to Join S&P SmallCap 600NASDAQ:ITOSiTeos Therapeutics Inc
08/08/202313h00GlobeNewswire Inc.iTeos Reports Second Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:ITOSiTeos Therapeutics Inc
26/06/202313h54Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ITOSiTeos Therapeutics Inc
16/06/202301h56Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ITOSiTeos Therapeutics Inc
22/05/202312h02Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ITOSiTeos Therapeutics Inc
10/05/202313h53Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:ITOSiTeos Therapeutics Inc
10/05/202313h11Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ITOSiTeos Therapeutics Inc
10/05/202313h01GlobeNewswire Inc.iTeos Reports First Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:ITOSiTeos Therapeutics Inc
27/04/202313h15Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:ITOSiTeos Therapeutics Inc
27/04/202313h10Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ITOSiTeos Therapeutics Inc
27/04/202313h06Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ITOSiTeos Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ITOS

Dernières Valeurs Consultées

EU
AF
Air FranceKLM
EU
VK
Vallourec
EU
PX4
SBF 120
EU
GLE
Societe Generale
EU
ML
Michelin
EU
MC
Lvmh Moet Hennessy Louis...
COIN
ETHUSD
Ethereum
EU
LR
Legrand
NYSE
MRK
Merck
NYSE
DIS
Walt Disney
NYSE
MCD
McDonalds
EU
EN
Bouygues
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés